Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LMI070 - SMN2 RNA splice modulator Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) NCT02268552 (CLMI070X2201) Type 1 spinal muscular atrophy Phase 1/2 39 Number of participants with adverse events (AEs) and serious adverse events (SAEs) Branaplam oral, once weekly: Part 1: 5 ascending doses Part 2: 2 different dose levels Part 3: patients continue on initial dose assigned in Part 1 or Part 2 Patients with type 1 spinal muscular atrophy Study Part 2: Q3-2020 (actual) Study Part 3: 2023 Publication 88 Investor Relations | Q2 2021 Results TBD NOVARTIS | Reimagining Medicine

View entire presentation